Table 1.

Randomized trials evaluating adjuvant therapy in elderly GBM patients included in analysis

Trial Registration	NCT00482677	ISRCTN81470623	NCT01502241#	NCT00430911
Publication	Perry et al. 2017 (NEJM)	Malmstrom et al. 2012 (Lancet Onc)	Wick et al. 2012 (Lancet Onc)	Keime-Guibert et al. 2007 (NEJM)	Roa et al. 2004 (JCO)
PubMed ID	28296618	22877848	22578793	17429084	15051755
Study years	2007–2013	2000–2009	2005–2009	2001–2007	1996–2001
Patients (n)	562	291	373	81	95
Sex
Male	61%	59%	47%	63%	58%
Female	39%	41%	53%	37%	42%
Age, minimum	65	60	65	70	60
Age, median (range)	73 (65–90)+	70 (60–83)*	72 (66–84)	73 (70–85)	72 (mean)
Performance status, min	ECOG 2	ECOG 2	KPS 60	KPS 70	KPS 50
Performance status, median	ECOG 1 (0–1, 77%)	ECOG 1 (0–1, 77%)	KPS 80	KPS 70	KPS 70
MGMT status
MGMT methylated	47% (165/354)	45% (91/203)	35% (73/209)	N/A	N/A
MGMT unmethylated	53% (189/354)	55% (112/203)	65% (136/209)	N/A	N/A
Unknown	208 (37%)	88 (30%)	164 (44%)	81 (100%)	95 (100%)
Extent of resection
Biopsy	32%	26%	39%	52%	39%
Partial or complete resection	68%	74%	61%	48%	61%
Randomization	RT-15 + TMZ vs RT-15	RT-30 vs RT-10 vs TMZ	RT-30 vs TMZ	RT-28 versus supportive care	RT-30 vs RT-15

^#Included GBM and anaplastic astrocytoma.

⁺Age 65–70: n = 82; age 71–75: n = 114; age 76+: n = 85.

*Age 60–70: n = 125; age 70+: n = 117.

RT-30 = 6 weeks [30 fractions] of RT (total dose 60 Gy).

RT-28 = 5.5 weeks [28 fractions] of RT (total dose 50.4 Gy).

RT-15 = 3 weeks [15 fractions] of RT (total dose 40.05 Gy).

RT-10 = 2 weeks [10 fractions] RT (total dose 34 Gy).

N/A = Not applicable.